Core Viewpoint - He Eye Hospital, a leading ophthalmology institution in Northeast China, is facing challenges due to management changes, underperformance of fundraising projects, and a significant decline in profits since its IPO in 2022 [1][2][3]. Group 1: Management Changes - In December 2025, the company experienced significant management changes, including the resignation of the general manager and the secretary of the board [8][9]. - The new general manager, He Xingru, is the son of the actual controllers, He Wei and He Xiangdong, indicating a continuation of family control [8][9]. Group 2: Financial Performance - He Eye Hospital's revenue for 2024 is projected to be 1.096 billion yuan, a decrease of 7.56% year-on-year, with a net loss of 27.3982 million yuan, a decline of 143.11% [2]. - The company reported a net profit of 54.3953 million yuan for the first three quarters of 2025, showing improvement compared to previous years, but the stock price continued to decline [8]. Group 3: Fundraising and Project Performance - The company raised approximately 1.296 billion yuan during its IPO, but many fundraising projects have not met expected returns or timelines [1][2]. - Specific projects, such as the Beijing and Chongqing new hospital projects, have incurred significant losses, with cumulative losses of 90.8468 million yuan and 69.5107 million yuan, respectively [3][6]. - The company has announced delays in project timelines, extending the expected operational status for several projects to 2026 and 2027 [5][6]. Group 4: Shareholder Actions - The fourth largest shareholder, Advanced Manufacturing Industry Investment Fund, plans to reduce its stake by up to 310,610 shares, representing 1.97% of the total shares [9][10]. - Previous reductions by the same fund have already occurred, indicating a trend of shareholder exits amid declining stock performance [10][12].

（文章来源：证券日报） 证券日报网讯 1月19日，爱尔眼科在互动平台回答投资者提问时表示，工作、生活的手机化持续增加用 眼时长和用眼强度，眼科服务需求实际在逐步扩大。 ...

Group 1 - The company announced that Mr. Zheng Chengjie has resigned from the position of co-secretary effective January 1, 2026 [1] - Mr. Zheng Chengjie has also resigned as the authorized representative under the Hong Kong Stock Exchange Listing Rules and as the legal representative for receiving legal documents in Hong Kong, effective January 1, 2026 [1] - Mr. Luo Weijian has been appointed as the new company secretary, authorized representative, and legal representative, effective January 1, 2026 [1]

Core Viewpoint - The company, Chaoyue Eye Care (02219), announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1: Buyback Details - The company will repurchase 110,000 shares at a total cost of HKD 296,900 [1] - The buyback price per share is set between HKD 2.68 and HKD 2.72 [1]

Group 1 - The core point of the news is that Huaxia Eye Hospital's stock has experienced a decline of 1.04%, with a total market value of 15.128 billion yuan and a cumulative drop of 0.6% over the last three days [1] - Huaxia Eye Hospital Group, established on August 12, 2004, specializes in ophthalmology services, with revenue composition as follows: refractive projects 36.90%, comprehensive optometry projects 24.04%, cataract projects 20.14%, posterior segment projects 12.94%, and others 5.99% [1] - The stock's trading volume was 36.5619 million yuan, with a turnover rate of 0.31% [1] Group 2 - Huaxia Eye Hospital's major circulating shareholder is Huabao Fund, which reduced its holdings in the Huabao CSI Medical ETF (512170) by 1.1664 million shares, now holding 7.1388 million shares, representing 2.17% of circulating shares [2] - The estimated floating loss for Huabao CSI Medical ETF today is approximately 1.3564 million yuan, with a cumulative floating loss of 785,300 yuan during the three-day decline [2] - The Huabao CSI Medical ETF was established on May 20, 2019, with a current scale of 26.404 billion yuan and a year-to-date return of 5.42%, ranking 3760 out of 4195 in its category [2]

朝聚眼科(02219)发布公告，于2025年12月29日该公司斥资27.03万港元回购10万股，回购价格为每股 2.66-2.71港元。 ...

希玛医疗近期回购情况, 回购日期回购均价回购股数回购金额本年累计回购股数2025-12-191.65918.20万30.20万3001.20万2025- 12-181.61832.00万51.78万2983.00万2025-12-021.75016.00万28.01万2951.00万2025-12-011.75013.20万 23.10万2935.00万2025-11-281.73322.00万38.13万2921.80万2025-11-271.73012.00万20.76万2899.80万 2025-11-261.73216.00万27.72万2887.80万2025-11-251.72020.00万34.41万2871.80万2025-11-241.71220.00 万34.24万2851.80万2025-11-211.74024.00万41.76万2831.80万2025-11-201.80612.00万21.67万2807.80万 2025-11-191.80220.00万36.04万2795.80万2025-11-181.79216.00万28.67万2775.80万2025-11-171.8086 ...

Group 1 - The company, Chaoyue Eye Care (02219), announced a share buyback on December 11, 2025, for a total expenditure of HKD 320,300 [1] - A total of 120,000 shares will be repurchased at a price range of HKD 2.63 to HKD 2.70 per share [1]

证券日报网讯12月4日，华厦眼科（301267）在互动平台回答投资者提问时表示，公司长期专注于眼科 医疗服务，已经建立了全国连锁运营的诊疗服务体系。公司正按照发展战略规划，通过自建及并购方 式，稳步推进全国医疗服务网络布局。 ...

Core Viewpoint - The company, Chaoyue Eye Care (02219), announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1 - The company will repurchase 120,000 shares at a total cost of HKD 308,400 [1] - The buyback is scheduled for November 26, 2025, reflecting a strategic move to enhance shareholder value [1]